Difficult-to-manage mucosal candidal infection has been a hallmark of individuals with advanced infection due to human immunodeficiency virus type 1. In this AIDS Commentary, Drs. Fichtenbaum and Powderly comprehensively review the literature and their experience with refractory candidiasis in such patients. Of interest is their delineation of resistance, a lack of susceptibility to an antifungal agent in vitro among patients with refractory or clinically unresponsive disease. These authors believe that the establishment of resistance should be based upon standards established by the National Committee on Clinical Laboratory Standards, which they propose to define as a failure to respond to systematic therapy with specific doses of itraconazole, fluconazole, or parenterally or orally administered amphotericin B within 14 days. There have been many definitions of ''refractory candidiasis,'' and the one proposed by these authors will be debated; however, this definition has the advantage of establishing a standard by which to judge the efficacy of their proposed algorithm for the treatment of persistent or refractory oropharyngeal candidal infections. Drs. Fichtenbaum and Powderly have performed a useful service in their attempt to bring coherence to the management of this common and often vexing problem.
Mucosal candidiasis is a common problem, and oropharyntolerated, and safe. Mucosal disease that is unresponsive to topical therapy or to ketoconazole usually responds to fluconageal candidiasis (OPC) was among the initial manifestations recognized in association with HIV infection [1, 2] . Since these zole. Fluconazole was the first triazole approved for use in the United States and is perhaps the most commonly used agent initial reports of OPC, this relatively easily manageable disease has become increasingly difficult to treat in some patient popufor the treatment of mucosal candidiasis. Finally, refractory OPC is difficult to treat and often requires the use of intravelations.
Refractory candidiasis has emerged as an important opportunous amphotericin B which is inconvenient, expensive, and toxic. nistic illness affecting patients with advanced HIV disease [3 -21] . The morbidity associated with refractory mucosal disease Refractory mucosal candidiasis is a relatively new problem. The incidence of azole failures, in particular fluconazole failcan be clinically significant. Progression to esophagitis and interference with adequate nutritional intake, weight loss, and ures, has not been well defined. There is no standard, accepted definition of a clinical failure. In addition, the mechanisms for inability to swallow oral medications may occur [22] .
Most of the reported therapeutic failures have occurred in refractory disease and resistance are incompletely understood. Furthermore, the optimal treatment for fluconazole-refractory patients who were treated with fluconazole. Fluconazole has been the focus of these reports for several reasons. It is a firstdisease is not known. Finally, there is very little information on how to prevent the development of refractory disease and line agent for the treatment of OPC as well as esophageal and vaginal candidiasis. Fluconazole is predictably absorbed, well the emergence of resistance. Over the past 2 years, several new drugs have become available for the treatment of fluconazolerefractory disease, new mechanisms of fungal resistance have been described, and several studies have further defined the epidemiology of clinical disease. Thus, it is important to review ment of refractory mucosal candidiasis.
We have developed a set of guidelines for defining refractory infections (table 2) . These guidelines are based on the premise that the failure to respond to treatment with standard doses of decreased in vitro susceptibility to a particular antimicrobial agent. Resistance has also been used to indicate clinical failure medications should be viewed as refractory disease. Although these definitions may seem somewhat arbitrary, they provide of therapy. This terminology is confusing. The term resistance should be reserved to indicate a lack of in vitro susceptibility.
an important starting point for developing a consensus on this issue, which is essential for comparing future studies of refracClinical failure, refractory disease, or clinically unresponsive disease are the terms that should be used to indicate episodes tory disease and for reducing the time that patients are exposed to ineffective treatment regimens. Topical therapy with nystatin of mucosal candidiasis that failed to respond to treatment.
Recently, a working group for the National Committee on or clotrimazole and oral therapy with ketoconazole are omitted from The definition of clinical failure has varied within the pubtion. This is particularly important in patients with advanced HIV infection who have hypochlorhydria or achlorhydria, lished literature; a consensus definition has not emerged. The important components of a definition of clinical failure should which may affect the absorption of ketoconazole or itraconazole [26 -27] . Drug interactions may also result in decreased include the organism responsible for the infection, the type of medication used, and the dose and the duration of therapy. One levels of antifungal medications (e.g., use of the rifamycins lowers levels of itraconazole) [28] . There are some patients alternative is to define clinical failures as the persistence or progression of disease despite the use of maximally tolerated doses of a particular medication for a duration normally ex- [40] . Thus, although initial retrospective reports suggested that the incidence organisms are recovered. In the absence of noncompliance, absorption, or drug distribution problems, there may be host of clinical failures of fluconazole might be substantially higher, the incidence is in fact probably no more than 5%, with the factors that explain some clinical failures. Thus, it is important to distinguish true in vitro drug resistance from clinical failures majority of those cases occurring in patients with advanced HIV disease. due to host factors, medication delivery, absorption, or metabolism problems.
There are several important caveats to consider in interpreting data on the incidence of refractory mucosal candidiasis. First, there are limited data on the incidence of non-fluconaThe Incidence and Prevalence of Resistant and zole-associated drug failures. Second, the major focus of the Refractory Disease published studies has been on refractory OPC, and there are limited data on esophageal or vaginal disease. The rate of Mucosal candidiasis is very common in HIV-infected patients. The incidence of this fungal infection increases as the fluconazole-refractory vaginal disease appears to be very low, and there have been only scattered reports of fluconazole-re-CD4
/ lymphocyte count decreases [29] . More than 60% of patients with CD4
/ lymphocyte counts of õ100/mm 3 will defractory vaginal candidiasis [41] . Finally, it is again important to note that all of these studies were completed before the velop OPC each year [29 -36] . Recurrent disease occurs in more than one-half of these patients [34 -36] . Esophageal canwidespread use of highly active antiretroviral therapy. Findings from informal surveys of various clinical centers suggest that didiasis affects 10% -20% of patients with AIDS [37] . The incidence of vaginal candidiasis is less well studied. In several the incidence of refractory mucosal candidiasis may well be declining. This decline is supported by recent evidence of slow studies, vaginal candidiasis was noted in 30% -60% of patients, rates similar to those for OPC [38 -39] . In a recent study of enrollment in trials of new therapies for refractory OPC. The rates of in vitro resistance to antifungal medications fluconazole prophylaxis for mucosal candidiasis, the incidence of vaginal candidiasis was 27% in the placebo group, with a have been studied more widely [17, 20 -21, 42 -52]. The incidence and prevalence of resistance varies widely in these studmedian duration of follow-up of 29 months [40] .
All of these studies were conducted before the introduction ies. Overall, the rates of fluconazole resistance vary from 5% to 56% [17, 20 -21, 42 -45] . The rates of ketoconazole and of highly active antiretroviral therapy. It is likely that the incidence of mucosal candidiasis will decline as more patients itraconazole resistance have been reported less frequently, but they vary from 0 to 25% [6, 46 -50] . Amphotericin B resistance receive this antiretroviral therapy.
There have been several retrospective studies of the incihas been reported but is extremely uncommon [48] . Much of the variance in the rates of in vitro resistance to dence of fluconazole-refractory OPC in clinic cohorts. Quereda et al. [20] reported a failure rate of 14% for fluconazole in a antifungal agents can be explained by several factors, including differences in the level of host immunosuppression and expocohort of 50 patients followed up prospectively in Spain. Others have reported a fluconazole-failure incidence of 6% -7% sure to antifungal agents, differences in the type of study (longitudinal vs. cross-sectional), differences in the prevalence of among HIV-infected patients with OPC [4 -5] . Bailey and colleagues [3] reviewed the records of 155 HIV-infected patients non-albicans species of Candida, and differences in the in vitro methods used to define resistance. For example, Chavanet et with CD4
/ lymphocyte counts of õ300/mm 3 and reported an incidence of fluconazole failures (with a dosage of §100 al. [51] conducted a cross-sectional study of 154 patients with HIV infection. Fluconazole resistance was present in 13.8% of mg/d for 10 days) of 5.8%. Many of these retrospective studies were performed on relatively small numbers of patients at sinthe C. albicans isolates, five of six C. glabrata isolates, one of five C. tropicalis isolates, and all three C. kruseii isolates. gle centers. Because of the regional differences in azole-use patterns, the variations in the level of immunosuppression of No resistance to ketoconazole, miconazole, or econazole was detected. Chavanet et al. used a microtiter broth dilution the populations under study, and the inherent statistical biases in these small retrospective reports, the incidence of fluconamethod and reported the results as an MIC 50 of each drug. The mean CD4 / lymphocyte counts were well above 100/mm 3 . In zole-refractory disease was not clear.
The published prospective information on the incidence of contrast, Korting and colleagues [42] studied 84 patients by using an MIC 30 and found much lower rates of resistance to refractory OPC is limited. We recently reported preliminary results from ACTG (AIDS Clinical Trials Group) 816, a proflucytosine, ketoconazole, and itraconazole in õ10% of 62 isolates. The CD4 / lymphocyte counts were not reported in spective, multicenter observational study of resistant mucosal candidiasis in patients with advanced HIV infection [25] . In that study, and nearly two-thirds of the patients had asymptomatic HIV infection or generalized lymphadenopathy. that study of 846 patients with advanced HIV disease, the annual incidence of fluconazole-refractory OPC was 4%. A In another study, St. Germain and colleagues [49] studied 250 isolates from 93 patients with HIV infection treated in a similar rate of fluconazole-refractory OPC was also recently reported in a large multicenter study of fluconazole prophylaxis randomized trial of ketoconazole vs. itraconazole. These investigators used a modified microtiter method for measuring susfor vaginal candidiasis in women. In that study the incidence / lymphocyte counts of §200/mm 3 . Over the course of 1 year, 35 of these served. First, resistance may emerge within the same strain of a colonizing organism over time [61] . Alternatively, a different patients were evaluated for fluconazole MICs, and there was a change for those who received fluconazole prophylaxis (i.e., species or strain of Candida may colonize some patients with AIDS [62] . The latter trend has also been described for neutrothe MIC 90 increased from 0.5 mg/mL to 8 mg/mL).
In summary, resistance is associated with greater immunopenic patients [63] . C. albicans is the most common species associated with mucosal disease and is also the leading organsuppression and more frequent exposure to antifungal agents. However, because of the methodological differences in survey ism associated with fluconazole treatment failures. Candida parapsilosis, C. tropicalis, C. kruseii, and C. glabrata have studies, it is impossible to draw meaningful conclusions about the true prevalence or incidence of in vitro resistance.
been implicated in mucosal infections and refractory disease, although at much lower rates than C. albicans.
Colonization with Candida species is an important predisRisk Factors for Refractory and Resistant Candidiasis
posing event for the occurrence of mucosal disease. Colonization with Candida species occurs in up to one-third of healthy Refractory candidiasis is almost always seen in patients with very advanced AIDS. Factors associated with refractory disease hosts [64] . Colonization occurs in two-thirds of patients with advanced HIV infection [44] . Colonization with a resistant can be divided into those related to the host, the organism, or the environment. It is likely that a combination of these factors organism may occur weeks to months before the development of refractory disease [44] . However, it is not always clear that is required for the development of refractory disease.
Host-related factors are important in the pathogenesis of organisms cultured from an asymptomatic individual are responsible for disease that occurs at a later date. OPC. The level of immunosuppression is paramount. In general, the incidence of OPC among HIV-infected individuals
The individual Candida strains that affect patients with HIV infection do not appear to be different from those that affect other without advanced immunodeficiency varies between 7% and 48% [53 -55] . Up to 92% of patients with progressive immunoimmunosuppressed hosts, and each patient appears to be infected with a unique, individual strain [65] . Furthermore, there are no deficiency will develop OPC [56] . The vast majority of fluconazole treatment failures have occurred in persons with very detectable differences in the virulence of strains isolated from HIV-infected and non-HIV-infected persons. There is little inforadvanced HIV disease [3 -12] . Few cases of fluconazole treatment failures have been reported among persons with CD4 / mation available on the virulence properties among strains that cause refractory disease and those that do not. It is curious that lymphocyte counts of ú50/mm 3 . In addition, a history of prior opportunistic illnesses such as Mycobacterium avium complex some animal models of mucosal candidiasis have demonstrated that organisms associated with refractory disease appear to be less (MAC) disease and toxoplasmosis have been associated with the occurrence of fluconazole treatment failures [44] . Although virulent (P. Fidel, personal communication). There are several mechanisms that explain in vitro resistance this association may simply represent a nonspecific measure of generalized, severe immunodeficiency, it is possible that to antifungals, including target alteration, reduced cell permeability, and active efflux of the drug from the cell. Some yeasts are some individuals may have specific defects that make them more susceptible to a variety of pathogens.
resistant to a single drug, whereas others are multidrug resistant. Azole resistance has been demonstrated in yeasts that contain The relationship between the level of immunosuppression and vaginal candidiasis may not be as strong. In one crossalterations in the enzymes that were the target of the drug's action or that were involved in ergosterol biosynthesis. The cytochrome sectional study of 833 HIV-infected women and 427 non-HIVinfected women, the incidence of vaginal candidiasis was simi-P-450-dependent 14a-sterol demethylase (P-450 DM ) and the D 5, 6 sterol desaturase are two enzymes that, when altered, result in lar (9%) in both groups [57] .
In addition to deficient cell-mediated immunity, there are azole resistance [66, 67] . Reduced cell permeability is another mechanism of azole resistance. For example, two strains of other host-related factors that may contribute to the occurrence of OPC, including diminished salivary flow rates, cigarette C. albicans that are impermeable to the triazole ICI 153066 have been isolated in cases of treatment failure [68] . These two strains smoking, blood-group secretor status, and the antimycotic constituents of saliva [31 -33, [69] reported an enpain, altered taste, and difficulty swallowing liquids and solids. ergy-dependent mechanism for fluconazole resistance in a strain Many patients are relatively asymptomatic, even in cases of of C. glabrata. extensive refractory disease. Refractory OPC typically presents The prevalence of these resistance mechanisms is unknown.
as pseudomembranous disease characterized by the occurrence Further, it is not clear whether certain mechanisms of resistance of painless white or tan plaques on the tongue, gums, buccal may be overcome by higher dosing of the drug. This is likely, membranes, or throat. The plaques are composed of necrotic since some patients exhibit only partial clinical responses to material, desquamated parakeratotic epithelia, hyphae, and lower doses but respond to treatment with higher doses of a yeast cells that do not penetrate beyond the stratum spinosum. given agent. In summary, resistance is a complex event with
Esophageal candidiasis is usually accompanied by OPC. multiple mechanisms. It may well be that several alterations are Dysphagia and odynophagia are typically described. In as many required to confer azole resistance [70] . Evaluation of isolates as 40% of patients with OPC, esophageal involvement may before and after the development of resistance will be useful be asymptomatic [73] . Occasionally, esophageal disease may in determining critical events that lead to refractory disease. present in the absence of clinically detectable oropharyngeal The single most important environmental factor in the develdisease. The onset of dysphagia in a patient with OPC is sugopment of resistance is the exposure to antifungal medications gestive of esophageal involvement. over time. Maenza et al. [8] reported a longer median duration
The diagnosis of refractory disease is made when persistent of exposure to antifungal therapy (419 days vs. 118 days; or progressive disease is observed after adequate treatment with P õ .001) and of systemic azole therapy (272 days vs. 14 days; an antifungal agent. In patients with candidiasis, cultures may P õ .001) among patients with fluconazole-refractory OPC be helpful in detecting pathogens with intrinsically higher resisthan among matched controls. In addition, these investigators tance to specific antifungal agents. However, the diagnosis of documented that lower median CD4
/ lymphocyte counts and refractory disease should not be made on the basis of recovery a history of more-frequent treated episodes of OPC were also of a resistant organism. For patients with refractory disease, associated with the development of fluconazole-refractory clinicians should always consider alternative diagnoses such OPC. It is not clear whether the total dose, duration, or the as herpes simplex, aphthous ulcers, oral hairy leukoplakia, and pattern of antifungal use is the most important determinant of histoplasmosis. the development of resistance.
One important hypothesis worth testing is whether continuTreatment ous or episodic exposure to azoles is more likely to lead to the emergence of resistant strains. This hypothesis is being studied Treatment of mucosal candidiasis is relatively simple, since in an ongoing prospective trial conducted by the ACTG and most types of disease respond to topical or systemic therapy. the Mycoses Study Group (MSG; ACTG 323/MSG 40). There Conversely, refractory candidiasis is often difficult to treat and are some data suggesting that resistance is more common with may become increasingly less responsive to therapy over time. episodic treatment. Heald and colleagues [71] reported that the The most important step is to determine what medications have intermittent use of fluconazole was more frequently associated been tried, what dosages have been used, and whether the with the emergence of more-resistant C. albicans and nonpatient was taking the prescribed therapy appropriately. On albicans species among persons with HIV infection. Finally, rare occasions, patients taking medications that affect the methe use of trimethoprim-sulfamethoxazole, antiretroviral tabolism of some antifungal agents, such as rifampin, may agents, or macrolide antibiotics does not appear to be associated present with clinically unresponsive disease [74] . Removal of with the development of fluconazole-refractory disease [25] .
the interacting medication or an increase in the dose of the There have been intriguing reports of person-to-person transantifungal agent may clear the infection. mission of resistant organisms leading to the development of In general, if a patient with oral candidiasis has failed to refractory disease. Barchiesi et al. [72] reported transmission of a respond to therapy with clotrimazole, nystatin, ketoconazole, genetically related fluconazole-resistant strain in a married couple.
or itraconazole tablets, most clinicians will use fluconazole Proof of this transmission hypothesis is hampered by the fact that (100 -200 mg daily for 7 -14 days). Patients who are unresponit is difficult to exclude the possibility that the organism was sive to fluconazole at a dose of 200 mg daily, given for 2 acquired from an unidentified other common source. The freweeks, are unlikely to respond to higher doses; however, there quency of this phenomenon is unknown; if it is confirmed and have been some reports of successful treatment using higher shown to be a common event, it may have important implications doses of fluconazole (400 -800 mg) in patients who have not for preventing the development of refractory disease.
responded to standard doses [75] .
Clinical Manifestations and Diagnosis
There are a number of options for the treatment of fluconazole-refractory disease (table 3) . There have been few conThe clinical manifestations of refractory candidiasis are similar to those of responsive disease. The distinction between trolled studies of these approaches and no comparative studies.
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Medication Dosage
Itraconazole capsules are generally ineffective. However, there has been greater success with the cyclodextrin solution candidiasis. Patients in whom treatment failed were defined as those unresponsive to 10 days of therapy with §100 mg of fluconazole daily. Response was considered partial or complete Parenteral amphotericin B remains the drug of choice for patients with severe disease or esophageal involvement. Typiby using a scoring system that included visible lesions, subjective symptoms, and the absence of adverse events. The total cally, patients respond to doses of 0.3 -0.5 mg/(kgrd). The duration of treatment is based on the response, but 7 -10 days clinical response rate was 65% (22 of 34 evaluable cases), with 24% of patients demonstrating a complete response. Two for OPC or vaginal disease and £21 days for esophageal disease are typically required. Some patients may require as much patients were unevaluable because they were receiving concomitant antifungal therapy, and two patients discontinued theras 1 mg/(kgrd) of parenteral amphotericin B for a response. There are few data on the use of liposomal preparations of apy because of nausea and vomiting. Fessel and colleagues [84] reported the efficacy of itraconaamphotericin B for refractory mucosal candidiasis.
Recently, oral itraconazole solution and oral amphotericin zole solution in 78 patients with fluconazole-refractory OPC. Patients were treated with 100 mg twice daily for £28 days. B solution have become available for the treatment of patients with refractory OPC. Amphotericin B oral suspension is an A complete clinical response was observed in 59% (40 of 68 evaluable cases). Improvement was noted in an additional 10 attractive candidate for treatment of fluconazole-resistant candidiasis because resistance to amphotericin B is uncommon cases. Mycological response was achieved in 27% (17 of 62 evaluable cases). All 22 patients who were followed up relapsed [76 -78] . Amphotericin B oral suspension was approved by the U.S. Food and Drug Administration in the 1960s for the a median of 13 days after the cessation of therapy. In the follow-up study of the complete responders (25 of 40 potential treatment of OPC; however, there is little published experience with oral amphotericin B for the treatment of fluconasubjects enrolled), Moskovitz et al. [85] reported a 52% relapse rate among patients receiving itraconazole solution three times zole-resistant thrush. Two small studies have demonstrated some success with relatively low doses of oral amphotericin weekly. Ten patients ultimately stopped receiving therapy because of adverse events, although only one patient's adverse B [79 -80] . In the first study, Dewsnup and Stevens [79] reported the successful treatment of four patients with an event was attributable to itraconazole. Overall, the response rate for fluconazole-refractory OPC to extemporaneous preparation of amphotericin B (1 mg in 5 mL of diluent four times daily). In the second study, five itraconazole solution is somewhere between 50% and 60%, and may be slightly lower for oral amphotericin B solution. patients received 5 mL of a 0.2 -1.0 mg/mL solution of amphotericin B five times daily [80] . All patients had an initial, Although the response rate with amphotericin B is generally lower than that reported with itraconazole solution, this finding although incomplete, response and relapsed within 1 -3 months. The ACTG recently completed an open-label trial of may well be explained by differences in study design including the response criteria, which was stricter in one trial of amphooral amphotericin B solution for patients with OPC that is refractory to fluconazole therapy. In that study, amphotericin tericin B oral solution.
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Other anecdotal approaches to fluconazole treatment failures have included the use of very-high-dose fluconazole, with or without 5-fluorocytosine. Gentian violet has occasionally been used successfully in difficult-to-treat patients. Some clinicians have opted to use a variety of topical agents along with systemic therapy. Improving the immunologic function of a patient may help in the treatment of clinically unresponsive disease. Indeed, treatment with protease inhibitors has been noted to result in clinical improvement in hard-to-treat cases [86] . We have used protease inhibitors to treat several patients with refractory candidiasis, with mixed results. Typically, patients may respond initially; however, in our experience, relapse is common. Granulocyte-macrophage colony-stimulating factor may also be of some value and is being assessed in an ongoing phase II trial. Finally, newer antifungal agents, including other triazoles and the Echinocandins, may be active against refractory candidiasis; however, there is little clinical experience with these agents.
Despite the efficacy of initial treatment, relapse rates are high among patients with refractory disease [84] . Patients universally require maintenance therapy to prevent recurrences. Itraconazole solution or amphotericin B oral solution may be quite useful in the prevention of recurrences. It is not clear what dose should be given, although some dose reduction may be possible. However, we suggest caution in reducing the dose and dosing interval. Suboptimal dosing of antifungal agents may preselect the more resistant strains to emerge more rapidly, tunistic illnesses; however, there are few available data on the The addition of another agent or the administration of adincidence of refractory candidiasis. Anecdotally, it has been junctive immunotherapy are the most common approaches. difficult to enroll patients in trials of therapeutic agents for the In conclusion, the optimal approach to fluconazole-refractory treatment of refractory candidiasis, suggesting that the use of disease is not known. It is unlikely that comparative studies of highly active antiretroviral therapy has altered the incidence different strategies will be performed because there are not of this disease. The institution of highly active antiretroviral enough patients with this disease for conclusive statistical analtherapy, with suppression of HIV replication, is probably the ysis. We have developed a standardized approach for the treatsingle most important method for prevention of refractory canment of patients who present with refractory disease (figure didiasis. 1). However, it is likely that such patients will require treatment Although mucosal candidiasis is common, antifungal prowith multiple medications to control their refractory disease.
phylaxis is typically not indicated in most patients with HIV infection. Indeed, one study of the use of fluconazole to prevent fungal infections did not demonstrate prolongation of survival among patients with advanced HIV disease [88] . Continuous Prevention of Fluconazole-Refractory Disease use of antifungal agents should be reserved for patients with Refractory and resistant candidiasis tends to occur in patients frequent or severe recurrences of mucosal candidiasis or for with advanced HIV disease who have been exposed to antifunthose who have systemic mycoses requiring maintenance supgal therapy on a chronic basis. Thus, the two most important pressive therapy. For patients with occasional disease or infreprinciples in avoiding refractory disease are to delay or reverse quent recurrences of OPC or vaginal candidiasis (fewer than the onset of immunosuppression and to eliminate unnecessary three episodes per year), we tend to treat each episode separately. exposure to antifungal therapy.
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